These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 12625833)
21. A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein(a) and homocysteine. Smolders RG; Vogelvang TE; Mijatovic V; van Baal WM; Neele SJ; Netelenbos JC; Kenemans P; van der Mooren MJ Maturitas; 2002 Feb; 41(2):105-14. PubMed ID: 11836041 [TBL] [Abstract][Full Text] [Related]
22. Effect of raloxifene and hormone therapy on serum markers of brain and whole-body cholesterol metabolism in postmenopausal women. Vogelvang TE; Mijatovic V; van der Mooren MJ; Pinsdorf U; von Bergmann K; Netelenbos JC; Lütjohann D Maturitas; 2005 Apr; 50(4):312-20. PubMed ID: 15780532 [TBL] [Abstract][Full Text] [Related]
24. Effects of combined supplementation with B vitamins and antioxidants on plasma levels of asymmetric dimethylarginine (ADMA) in subjects with elevated risk for cardiovascular disease. Schmitt B; Wolters M; Kressel G; Hülsmann O; Ströhle A; Kühn-Velten WN; Lichtinghagen R; Bub A; Barth SW; Stichtenoth DO; Hahn A Atherosclerosis; 2007 Jul; 193(1):168-76. PubMed ID: 16876171 [TBL] [Abstract][Full Text] [Related]
25. Effect of conjugated equine estrogen in combination with two different progestogens on the risk factors of coronary heart disease in postmenopausal Chinese women in Taiwan: a randomized one-year study. Chang TC; Lien YR; Chen M; Cheng SP; Chen RJ; Chow SN Acta Obstet Gynecol Scand; 2004 Jul; 83(7):661-6. PubMed ID: 15225192 [TBL] [Abstract][Full Text] [Related]
26. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study. de Valk-de Roo GW; Stehouwer CD; Meijer P; Mijatovic V; Kluft C; Kenemans P; Cohen F; Watts S; Netelenbos C Arterioscler Thromb Vasc Biol; 1999 Dec; 19(12):2993-3000. PubMed ID: 10591680 [TBL] [Abstract][Full Text] [Related]
27. Effect of raloxifene on activated protein C (APC) resistance in postmenopausal women and on APC resistance and homocysteine levels in elderly men: two randomized placebo-controlled studies. Duschek EJ; Neele SJ; Thomassen MC; Rosing J; Netelenbos C Blood Coagul Fibrinolysis; 2004 Oct; 15(8):649-55. PubMed ID: 15613919 [TBL] [Abstract][Full Text] [Related]
28. Determination of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine in biological samples by HPLC. Teerlink T Methods Mol Med; 2005; 108():263-74. PubMed ID: 16028689 [TBL] [Abstract][Full Text] [Related]
29. Oestrogen replacement therapy reduces total plasma homocysteine and enhances genomic DNA methylation in postmenopausal women. Friso S; Lamon-Fava S; Jang H; Schaefer EJ; Corrocher R; Choi SW Br J Nutr; 2007 Apr; 97(4):617-21. PubMed ID: 17349072 [TBL] [Abstract][Full Text] [Related]
30. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases. Böger RH; Bode-Böger SM Semin Thromb Hemost; 2000; 26(5):539-45. PubMed ID: 11129410 [TBL] [Abstract][Full Text] [Related]
31. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. Prestwood KM; Gunness M; Muchmore DB; Lu Y; Wong M; Raisz LG J Clin Endocrinol Metab; 2000 Jun; 85(6):2197-202. PubMed ID: 10852452 [TBL] [Abstract][Full Text] [Related]
32. Regular physical exercise normalizes elevated asymmetrical dimethylarginine concentrations in patients with type 1 diabetes mellitus. Mittermayer F; Pleiner J; Krzyzanowska K; Wiesinger GF; Francesconi M; Wolzt M Wien Klin Wochenschr; 2005 Dec; 117(23-24):816-20. PubMed ID: 16437318 [TBL] [Abstract][Full Text] [Related]
33. Effects of conjugated oestrogen and droloxifene on the renin-angiotensin system, blood pressure and renal blood flow in postmenopausal women. Seely EW; Brosnihan KB; Jeunemaitre X; Okamura K; Williams GH; Hollenberg NK; Herrington DM Clin Endocrinol (Oxf); 2004 Mar; 60(3):315-21. PubMed ID: 15008996 [TBL] [Abstract][Full Text] [Related]
34. Incidence of urinary incontinence in postmenopausal women treated with raloxifene or estrogen. Goldstein SR; Johnson S; Watts NB; Ciaccia AV; Elmerick D; Muram D Menopause; 2005 Mar; 12(2):160-4. PubMed ID: 15772563 [TBL] [Abstract][Full Text] [Related]
35. Homocysteine in postmenopausal women and the importance of hormone replacement therapy. Mijatovic V; van der Mooren MJ Clin Chem Lab Med; 2001 Aug; 39(8):764-7. PubMed ID: 11592448 [TBL] [Abstract][Full Text] [Related]
37. Conjugated equine estrogen, raloxifene and arterial stiffness in postmenopausal women. Dias AR; de Mello NR; Eluf Gebara OC; Nussbacher A; Wajngarten M; Petti DA Climacteric; 2008 Oct; 11(5):390-6. PubMed ID: 18781483 [TBL] [Abstract][Full Text] [Related]
38. Effect of hormone replacement therapy and tibolone on serum leptin levels in postmenopausal women. Lambrinoudaki IV; Christodoulakos GE; Panoulis CP; Rizos DA; Dendrinos SG; Liakakos T; Augoulea AD; Creatsas GC Maturitas; 2004 Jun; 48(2):107-13. PubMed ID: 15172084 [TBL] [Abstract][Full Text] [Related]
39. The effect of hormone replacement therapy on the levels of serum lipids, apolipoprotein AI, apolipoprotein B and lipoprotein (a) in Turkish postmenopausal women. Bayrak A; Aldemir DA; Bayrak T; Corakçi A; Dursun P Arch Gynecol Obstet; 2006 Aug; 274(5):289-96. PubMed ID: 16810536 [TBL] [Abstract][Full Text] [Related]
40. Raloxifene reduces impedance to flow within the uterine artery in early postmenopausal women: a 2-year randomized, placebo-controlled, comparative study. Post MS; van der Mooren MJ; van Baal WM; Neele SJ; Netelenbos JC; Kenemans P Am J Obstet Gynecol; 2001 Sep; 185(3):557-62. PubMed ID: 11568777 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]